ESMO 2025 – Sanofi takes aim at Lutathera
But Perspective sinks again.
ESMO 2025 preview – Sanofi’s lead shot gets a boost
The group toplines a phase 2 win with Alphamedix.
Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
